Publicly funded opioid abuse therapy costeffective in USA

Publicly funded opioid abuse therapy costeffective in USA PharmacoEconomics & Outcomes News 792, p25 - 2 Dec 2017 Publicly funded opioid abuse therapy cost effective in USA Publicly funded opioid abuse therapy (OAT) appears to be cost effective, according to findings of a US study published in Annals of Internal Medicine. A semi-Markov model was used to evaluate the cost effectiveness and budget impact of immediate access to opioid abuse therapy with methadone in a hypothetical population of patients 35 years of age with opioid abuse disorder (primarily due to heroin) presenting at publicly funded treatment centers in California, compared with the standard of care (short- term medically managed withdrawal), from a societal perspective over a lifetime time horizon. The model was populated with data from linked treatment and criminal justice administrative databases. Immediate access to opioid abuse therapy was estimated to gain 0.42 additional QALYs compared with the standard of care and to reduce total costs by $78 257 over a lifetime. Opioid abuse therapy was therefore dominant (more effective and less costly). It was estimated that treatment of all patients with opioid use disorder in California in 2014 with immediate opioid abuse therapy would achieve total lifetime savings $3.8 billion. Sensitivity analysis found that opioid abuse therapy was cost effective in 99.6% of simulations. "Our findings further underline the need for widespread and unencumbered access to evidence- based treatment of opioid use disorder to reduce the burden to society of the current prescription opioid and heroin use epidemic," the authors commented. * 2016 US dollars Krebs E, et al. Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California Annals of Internal Medicine : 21 Nov 2017. Available from: URL: http://doi.org/10.7326/M17-0611 803284965 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Publicly funded opioid abuse therapy costeffective in USA

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/publicly-funded-opioid-abuse-therapy-costeffective-in-usa-lXxFqzhXqc
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4548-9
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p25 - 2 Dec 2017 Publicly funded opioid abuse therapy cost effective in USA Publicly funded opioid abuse therapy (OAT) appears to be cost effective, according to findings of a US study published in Annals of Internal Medicine. A semi-Markov model was used to evaluate the cost effectiveness and budget impact of immediate access to opioid abuse therapy with methadone in a hypothetical population of patients 35 years of age with opioid abuse disorder (primarily due to heroin) presenting at publicly funded treatment centers in California, compared with the standard of care (short- term medically managed withdrawal), from a societal perspective over a lifetime time horizon. The model was populated with data from linked treatment and criminal justice administrative databases. Immediate access to opioid abuse therapy was estimated to gain 0.42 additional QALYs compared with the standard of care and to reduce total costs by $78 257 over a lifetime. Opioid abuse therapy was therefore dominant (more effective and less costly). It was estimated that treatment of all patients with opioid use disorder in California in 2014 with immediate opioid abuse therapy would achieve total lifetime savings $3.8 billion. Sensitivity analysis found that opioid abuse therapy was cost effective in 99.6% of simulations. "Our findings further underline the need for widespread and unencumbered access to evidence- based treatment of opioid use disorder to reduce the burden to society of the current prescription opioid and heroin use epidemic," the authors commented. * 2016 US dollars Krebs E, et al. Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California Annals of Internal Medicine : 21 Nov 2017. Available from: URL: http://doi.org/10.7326/M17-0611 803284965 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off